U.S. News & World Report Honors
7 SynCardia Certified Centers
Among "Best Children's Hospitals"
for Cardiology and Heart Surgery
Two Additional Top Children's Hospitals Ready to Perform 1st SynCardia Total Artificial Heart Implant
TUCSON, Ariz. – June 13, 2013 – SynCardia Systems, Inc., manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that U.S. News & World Report has named seven SynCardia Certified Centers among the nation's "Best Children's Hospitals" for cardiology and heart surgery in its annual rankings for 2013-2014.
"The SynCardia temporary Total Artificial Heart has opened the flood gates in respect to the treatment possibilities for a quickly growing population of children in heart failure, including adolescents suffering from chronic rejection of their transplanted heart, end-stage heart failure accompanied by multiple congenital defects and a late-stage failing Fontan circulation," said Dr. David L.S. Morales, chief of pediatric cardiothoracic surgery at Cincinnati Children's Hospital Medical Center, which ranked in the top five.
SynCardia Certified Centers included in the list were:
- #2 Children's Hospital of Philadelphia (CHOP)
- #3 Texas Children's Hospital
- #5 Cincinnati Children's Hospital Medical Center
- #11 Children's Hospital of Wisconsin
- #26 Mattel Children's Hospital UCLA
- #32 Shands Hospital for Children at the University of Florida
- #34 Phoenix Children's Hospital
In addition to the seven hospitals listed above, #9 Lucile Packard Children's Hospital at Stanford and #43 Arkansas Children's Hospital have completed the first two phases of SynCardia's four-phase certification program and are ready to perform their first proctored implant once an appropriate patient has been identified.
Clinical research, surgical survival and ability to prevent bloodstream infections were among the factors making up 75% of the score used for the rankings. The other 25% reflects how many of 450 pediatric cardiologists and heart surgeons surveyed in 2011, 2012 and 2013 recommended the hospital.
CAUTION - The Freedom® portable driver is an investigational device, limited by United States law to investigational use.
About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end stage heart failure affecting both sides of the heart (biventricular failure). More than 400 SynCardia Total Artificial Heart implants have been performed since January 2011. The SynCardia Heart has provided almost 130,000 patient days of support from nearly 1,300 implants. The youngest patient to receive a SynCardia Heart was 9 years old; the oldest was 76 years old.
Similar to a heart transplant, the SynCardia Total Artificial Heart replaces both failing heart ventricles and the four heart valves. It is the only device that eliminates the symptoms and source of end stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at 97 SynCardia Certified Centers worldwide with 39 others in the process of certification.
The Total Artificial Heart provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.